27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Puma Biotechnology Inc (NYSE: PBYI) shares were trading steadily lower Wednesday. Earlier in the day, traders were passing around unconfirmed chatter that at these levels, Puma's secondary offering might be pulled.
TheStreet's Adam Feuerstein, arguably the most noted biotech reporter around, Tweeted that he's "hearing weak investor demand for stock offering announced last night."
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Earlier Wednesday afternoon, sources close to Puma's secondary offering told Benzinga Pro that investor demand is "very weak," and were hearing bids have been in the range of $40-$42 per share for only half the offering. Sources suggested bankers will hold a call with Puma at 2 p.m. ET to consider the fate of the secondary.
Benzinga Pro heard from another source close to the deal that Puma Biotech is discussing a debt deal instead of an equity deal. For a little background, a debt deal involves borrowing money to be repaid, plus interest; Equity deal involves raising money by selling interests in the company.
Shares of Puma Biotech traded recently at $42.85, down more than 18 percent on the day.
Update, 3:33 p.m. ET: Source close to the secondary deal tells Benzinga that Puma will go ahead with the offering. The deal is not fully covered, but is expected to be in the $40-$42 per share range.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.